moneyheap
ACAD · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Acadia Pharmaceuticals Inc. (ACAD) stock moving?
ACAD fell about 22% on Nov 9, closing at $16.50 from $21.23 on 12.15M shares, roughly six times its prior 12-day average of about 2.0M. The provided news does not explain that drop; the Nov 10 patent-appeal item is labelled as previously reported, so a link is unconfirmed. The stock rebounded 11% to $18.28 on Nov 10 on 6.35M shares but remains about 14% below the Nov 6 close. Fundamentals from the Q3 release are solid: revenue of $342M (up 22%) and EPS of $0.31 beat estimates, and DAYBUE guidance was raised to $505-520M while total sales guidance was narrowed to $1.265-1.295B. Analysts remain positive, with price targets of $30-41 and Buy or Outperform ratings after the report. Risks include the NUPLAZID patent appeal decision expected in the first half of 2027, and the Oct 23 retirement of the head of R&D, who stays as a consultant through Dec 31. Near-term catalysts are the remlifanserin data at CTAD on Nov 17, the ACP-211 MDD readout in 2H 2027, and the remlifanserin LBDP readout guided for Q4 2027.
News behind the analysis
- Reported Earlier, Acadia Says Federal Circuit Heard Oral Arguments In NUPLAZID 34 Mg Capsule Patent Appeal, Expects Decision In First Half Of 2027Acadia said the Federal Circuit heard oral arguments in the NUPLAZID 34 mg capsule patent appeal and expects a decision in the first half of 2027. The item is labelled as previously reported.
- Acadia Pharmaceuticals to Present Remlifanserin Data at 2026 CTAD ConferenceAcadia will present two data presentations on Alzheimer's disease psychosis and remlifanserin at the 2026 CTAD conference. The company's Q3 release notes the presentations take place on November 17.
- RBC Capital Markets Raises Price Target on Acadia PharmaceuticalsRBC raised its price target on Acadia to $41 from $31 and kept an Outperform rating.
- Canaccord Genuity Maintains Buy on Acadia Pharmaceuticals, Raises Price Target to $38Canaccord Genuity kept its Buy rating on Acadia and raised its price target to $38.
- Deutsche Bank Adjusts ACADIA Pharmaceuticals Price Target to $30Deutsche Bank cut its price target on Acadia to $30 from $31 and maintained a Buy rating.
- RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Raises Price Target to $38RBC raised its price target on Acadia to $38 from $36 and kept an Outperform rating, citing continued DAYBUE momentum.
- Acadia Pharmaceuticals Reports Third Quarter 2026 Financial ResultsQ3 total revenues were $342 million, up 22% year over year. DAYBUE net sales were $140 million, up 39%, and NUPLAZID net sales were $202 million.
- ACADIA Pharmaceuticals Narrows FY2026 Sales Guidance from $1.240B-$1.300B to $1.265B-$1.295B vs $1.272B EstAcadia narrowed its FY2026 sales guidance to $1.265B-$1.295B and raised its DAYBUE net sales guidance to $505-$520 million. The company guided both ranges against a $1.272B consensus.
- ACADIA Pharmaceuticals Q3 EPS $0.31 Beats $0.20 Estimate, Sales $342.291M Beat $332.468M EstimateAcadia reported Q3 EPS of $0.31 against a $0.20 estimate and sales of $342.291M against a $332.468M estimate.
About Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals is a San Diego biopharmaceutical company that sells medicines for neurological and rare diseases. It is already profitable, which is unusual for a mid-sized biotech, because of two approved drugs: NUPLAZID for hallucinations and delusions linked to Parkinson's disease, and DAYBUE, the first approved treatment for Rett syndrome.
How it makes money
Almost all of its revenue comes from net product sales of its two drugs. In Q3 2026 total revenue was about $342 million, made up of about $202 million from NUPLAZID (roughly 60%) and about $140 million from DAYBUE (roughly 40%). DAYBUE is the faster-growing of the two. For full-year 2026 the company guided to roughly $1.27–1.30 billion in total revenue, including about $505–520 million from DAYBUE. It spends part of its profits on research into pipeline drugs such as remlifanserin, which is being tested for psychosis in Alzheimer's disease.
What usually moves ACAD
- DAYBUE sales growth and international rollout
- NUPLAZID sales and patent/generic competition timing
- Clinical trial readouts (e.g., remlifanserin in Alzheimer's psychosis)
- FDA regulatory decisions
- Drug pricing and reimbursement policy